Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir

Criteria

Inclusion Criteria:

• Type 1 diabetes

• Type 2 diabetes

• Candidates of use of a basal insulin as part of their diabetes regimen

Exclusion Criteria:

• Unwilling to adhere to therapy or follow up

• Pregnancy